National Institute for Health and Clinical Excellence (NICE)
Tailored support should be offered to those affected by suspected suicide, says NICE
Providing support after a suspected suicide can reduce this risk, especially when tailored to the person’s needs.
People bereaved or affected by a suspected suicide should be given information and offered tailored support, NICE has said.
On World Suicide Prevention Day 2019, NICE has published its quality standard on suicide prevention – covering five key ways to reduce suicide and help people bereaved or affected by suicide.
The Office for National Statistics published data which showed the suicide rate in the UK has risen for the first time since 2013, with 11.2 deaths recorded as suicide per 100,000 people in 2018 - up from 10.1 in 2017.
Those who are bereaved or affected by a suspected suicide are themselves at increased risk of suicide.
Providing support after a suspected suicide can reduce this risk, especially when tailored to the person’s needs. It is important to identify people who may need support as soon as possible so that they can be given practical information and access support if, and when, they need to.
Professor Gillian Leng, deputy chief executive and director of health and social care at NICE yesterday said:
“Suicide can have a devastating and traumatic experience for anyone dealing with the loss of a loved one. It is a difficult subject to talk about and too often it’s not clear what help is available.
“Bereavement support can help reduce the risk of those affected by a suicide taking their own life. It is important that service providers such as police, hospitals, ambulance services and GPs identify people to give information to and to ask if they need help.
“No one should have to go through the unexpected death of someone dear to them alone and by offering information and tailored support, those affected can be supported both emotionally and practically.”
NICE has said that tailored support should be focused on the person’s individual needs. As well as professional support, it could include:
- support from trained peers who have been bereaved or affected by a suicide or suspected suicide
- adjustments to working patterns or the regime in residential custodial and detention settings
- other support identified in Public Health England’s Support after a suicide: a guide to providing local services and the National Suicide Prevention Alliance’s Support after a suicide: developing and delivering local bereavement support services.
A booklet developed by Public Health England and the National Suicide Prevention Alliance – Help is at Hand – has been highlighted as a good resource offering emotional and practical support/advice for those left bereaved by a suspected suicide.
Amy Meadows, whose mother suddenly took her own life following a short but intense period of depression and who helped write Help is at Hand, said:
“When I lost my mum to suicide ten years ago, my family didn’t get any information to explain what to expect or advice about where to turn for help despite the trauma and shock of our loss, and the fact that we instantly became at a greater risk of taking our own lives. People bereaved by suicide need, and deserve, support, for whilst everyone’s grief is unique, much can be gained by sharing experiences and receiving tailored help.
‘Help is at Hand’ offers people the chance to read about other’s experiences and alongside local support I hope it offers comfort and reassurance that no-one needs to tackle the grief of suicide alone, and that it helps to talk about what has happened.”
As part of the Long Term Plan, NHS England has committed to ensuring all areas in the country are funded to develop bereavement support services for families and staff who are bereaved by suicide.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Three areas where NICE's collaboration with CMAC can make a difference17/09/2019 13:15:00
Heidi Livingstone, senior public involvement adviser within NICE's Public Involvement Programme, reflects on the partnership with CMAC, 17 September 2019.
Children with rare inherited condition to benefit from drug through managed access agreement12/09/2019 16:25:00
It is estimated that in the UK there are around 30 to 50 children living with the condition.
Applications now open for NICE’s prestigious fellows and scholars programmes12/09/2019 10:15:00
Recruitment for the 2020 intake is open until 28 October 2019
NICE recommends novel gene therapy treatment for rare inherited eye disorder04/09/2019 14:15:00
It's estimated that 86 people would be eligible for treatment with voretigene neparvovec in England
NICE to work with company on addressing issues in appraisals of cannabidiol for treating difficult to control epilepsies23/08/2019 13:15:00
NICE has today (23 August 2019) announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating 2 types of severe treatment-resistant epilepsy.
Sir Andrew Dillon to stand down as NICE chief executive22/08/2019 12:15:00
Chief executive has been at the helm of the institute since it was founded in April 1999.
NICE draft guidance and NHS England review highlight need for more research on cannabis-based medicinal products08/08/2019 15:15:00
NICE has today (8 August 2019) published its draft recommendations on the use of cannabis-based medicinal products following a comprehensive evaluation of their clinical and cost-effectiveness
New lung cancer treatment option approved by NICE08/08/2019 12:15:00
Another new life-extending treatment for some people with lung cancer is to be made available on the Cancer Drugs Fund (CDF) following its approval by NICE in draft guidance published today (8 August 2019).
NICE recommends additional treatment option for people with early breast cancer08/08/2019 09:15:00
NICE yesterday (7 August 2019) published a draft guidance recommending neratinib as an additional treatment for some people with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.